These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36397196)

  • 1. Mobocertinib (Exkivity) for non-small cell lung cancer.
    Med Lett Drugs Ther; 2022 Nov; 64(1664):e197-e198. PubMed ID: 36397196
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting EGFR Exon 20 Insertion Mutation in Non-small cell Lung Cancer: Amivantamab and Mobocertinib.
    Russell MC; Garelli AM; Reeves DJ
    Ann Pharmacother; 2023 Feb; 57(2):198-206. PubMed ID: 35652704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matching-adjusted indirect comparison of amivantamab vs mobocertinib in platinum-pretreated
    Kim TM; Girard N; Leighl NB; Sabari J; Rahhali N; Schioppa CA; Diels J; Sermon J; Chandler C; Kapetanakis V; Jain R; Li T; Sanden SV
    Future Oncol; 2024 Mar; 20(8):447-458. PubMed ID: 37882460
    [No Abstract]   [Full Text] [Related]  

  • 4. Amivantamab (Rybrevant) for non-small cell lung cancer.
    Med Lett Drugs Ther; 2022 Nov; 64(1663):e184-e185. PubMed ID: 36384764
    [No Abstract]   [Full Text] [Related]  

  • 5. Mobocertinib (TAK-788): A Targeted Inhibitor of
    Gonzalvez F; Vincent S; Baker TE; Gould AE; Li S; Wardwell SD; Nadworny S; Ning Y; Zhang S; Huang WS; Hu Y; Li F; Greenfield MT; Zech SG; Das B; Narasimhan NI; Clackson T; Dalgarno D; Shakespeare WC; Fitzgerald M; Chouitar J; Griffin RJ; Liu S; Wong KK; Zhu X; Rivera VM
    Cancer Discov; 2021 Jul; 11(7):1672-1687. PubMed ID: 33632773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mobocertinib: First Approval.
    Markham A
    Drugs; 2021 Nov; 81(17):2069-2074. PubMed ID: 34716908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repotrectinib (Augtyro) for non-small cell lung cancer.
    Med Lett Drugs Ther; 2024 Feb; 66(1696):e36-e37. PubMed ID: 38412271
    [No Abstract]   [Full Text] [Related]  

  • 8. Positive progress for non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: A novel targeted therapy option.
    Zhang W; Dong X
    J Oncol Pharm Pract; 2021 Dec; 27(8):2007-2009. PubMed ID: 34569378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brigatinib (Alunbrig) for non-small cell lung cancer.
    Med Lett Drugs Ther; 2018 Apr; 60(1545):e72-e73. PubMed ID: 29667950
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and Safety of Osimertinib in a Hemodialysis Patient With Advanced Non-Small Cell Lung Cancer.
    Iwafuchi Y; Saito I; Narita I
    Ther Apher Dial; 2017 Aug; 21(4):416-417. PubMed ID: 28332292
    [No Abstract]   [Full Text] [Related]  

  • 11. Mobocertinib in non-small cell lung cancer.
    Liu S; Lowder KE
    Drugs Today (Barc); 2022 Nov; 58(11):523-530. PubMed ID: 36422513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Papulopustules and paronychia in a lung carcinoma.
    Thakur V; Daroach M; Kumaran MS
    Eur J Intern Med; 2019 Apr; 62():e5-e6. PubMed ID: 30297249
    [No Abstract]   [Full Text] [Related]  

  • 13. High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer.
    Fujita K; Hirose T; Kusumoto S; Sugiyama T; Shirai T; Nakashima M; Akiyama Y; Sasaki Y
    Lung Cancer; 2014 Oct; 86(1):113-4. PubMed ID: 25123334
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiovascular safety of novel non-small cell lung cancer oncotherapy in a patient treated with novel generations of tyrosine kinase inhibitors.
    Szymański FM; Płatek AE; Dziadziuszko R; Łęgosz P; Palczewski P
    Kardiol Pol; 2018; 76(3):670. PubMed ID: 29558014
    [No Abstract]   [Full Text] [Related]  

  • 15. Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure-Response Analyses of a Pivotal Phase I/II Study.
    Gupta N; Largajolli A; Witjes H; Diderichsen PM; Zhang S; Hanley MJ; Lin J; Mehta M
    Clin Pharmacol Ther; 2022 Aug; 112(2):327-334. PubMed ID: 35467009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
    Van Sebille YZ; Gibson RJ; Wardill HR; Bowen JM
    Curr Opin Support Palliat Care; 2016 Jun; 10(2):152-6. PubMed ID: 27035390
    [No Abstract]   [Full Text] [Related]  

  • 17. Afatinib (Gilotrif) for advanced non-small cell lung cancer.
    Med Lett Drugs Ther; 2015 May; 57(1469):e82-3. PubMed ID: 26039556
    [No Abstract]   [Full Text] [Related]  

  • 18. Amivantamab: a monoclonal EGFR-MET bispecific antibody for EGFR exon 20 insertion in non-small cell lung cancer.
    Xie Y; Lu Q; Wang JQ; Bo L; Ashby CR; Chen ZS
    Drugs Today (Barc); 2022 Aug; 58(8):389-398. PubMed ID: 35983925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
    Qi YT; Hou Y; Qi LC
    Technol Cancer Res Treat; 2020; 19():1533033820940426. PubMed ID: 32723164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer.
    Hong S; Gao F; Fu S; Wang Y; Fang W; Huang Y; Zhang L
    JAMA Oncol; 2018 May; 4(5):739-742. PubMed ID: 29596544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.